Polyamidoamine Dendrimer Hydrogel for Enhanced Delivery of Antiglaucoma Drugs
Dendrimer hydrogel (DH), made from ultraviolet-cured polyamidoamine dendrimer G3.0 tethered with three polyethylene glycol (PEG, 12,000 Da)-acrylate chains (8.1% w/v) in pH 7.4 phosphate buffered saline (PBS), was studied for the delivery of brimonidine (0.1% w/v) and timolol maleate (0.5% w/v), two antiglaucoma drugs. DH was found to be mucoadhesive to mucin particles and nontoxic to human corneal epithelial cells. DH increased the PBS solubility of brimonidine by 77.6% and sustained the in vitro release of both drugs over 56-72 hours. As compared to eye drop formulations (PBS-drug solutions), DH brought about substantially higher human corneal epithelial cells uptake and significantly increased bovine corneal transport for both drugs. DH increased timolol maleate uptake in bovine corneal epithelium, stroma, and endothelium by 0.4- to 4.6-fold. This work demonstrated that DH can enhance the delivery of antiglaucoma drugs in multiple aspects and represents a novel platform for ocular drug delivery. From the Clinical Editor: Dendrimer hydrogel was studied as agent for simultaneous delivery of two anti-glaucoma drugs, one hydrophobic and one hydrophilic. Superiority over standard PBS-based formulation was clearly demonstrated for both drugs. The work may be a novel platform for ocular drug delivery.
C. A. Holden et al., "Polyamidoamine Dendrimer Hydrogel for Enhanced Delivery of Antiglaucoma Drugs," Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 8, no. 5, pp. 776-783, Elsevier Inc., Jul 2012.
The definitive version is available at https://doi.org/10.1016/j.nano.2011.08.018
Chemical and Biochemical Engineering
Keywords and Phrases
Combination drug formulation; Dendrimer; Glaucoma; Hydrogel
International Standard Serial Number (ISSN)
Article - Journal
© 2012 Elsevier Inc., All rights reserved.
01 Jul 2012